MIA overexpression was observed in 13 of 30 head and neck SCCs (43.3%), 4 of 10 ESCCs (40%), 10 of 35 gastric adenocarcinomas (28.6%) (Figure 1A), 11 of 35 colorectal adenocarcinomas (31.4%), 6 of 18 lung SCCs (33.3%), 1 of 3 cutaneous SCCs (33.3%), 2 of 7 mammary invasive ductal carcinomas (28.6%) (Figure 1B), 8 of 21 cervical SCCs (38.1%), 2 of 6 prostatic adenocarcinomas (33.3%), and 2 of 8 testicular seminomas (25%) (Figure 1C). The gene discussed is MIA; the disease is prostate adenocarcinoma.